Institutes for Life Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China.
National Engineering Research Center for Tissue Restoration and Reconstruction, and Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, South China University of Technology, Guangzhou, 510006, P. R. China.
Small. 2019 Sep;15(36):e1902022. doi: 10.1002/smll.201902022. Epub 2019 Jul 18.
The cell nucleus-targeted delivery of therapeutic agents plays a critical role in cancer therapy, since the biological target of many anticancer therapeutics is the cell nucleus. However, multiple physiological barriers limit the delivery efficiency of free drugs, resulting in unsatisfactory therapeutic effects. Herein, thioketal crosslinked polyphosphoester-based nanoparticles with a tumor acidity (pH )-sensitive transactivator of transcription (TAT) peptide (DA-masked TAT-decorating reactive oxygen species (ROS)-sensitive Ce6/DOX-loaded hyperbranched nanoparticles ( TRCD)) are explored for cascade nucleus-targeted drug delivery. Following administration, TRCD experiences prolonged circulation by masking the targeting effect of its TAT peptide and then achieves enhanced tumor cell uptake and improved translocation into the perinuclear region by reactivating the TAT targeting capability in tumor tissue. Subsequently, ROS generated by TRCD under 660 nm laser not only disrupts the nuclear membrane to allow entry into the nuclei but also triggers intracellular release of the payload in the nuclei. As evidenced by in vivo experiments, such pH /photo dual-sensitive polymeric nanocarriers offer remarkable therapeutic effects, efficiently suppressing tumor growth. This multistage cascade nucleus-targeted drug delivery concept provides new avenues to develop nucleus-targeted drug delivery systems.
治疗剂的靶向细胞内递送在癌症治疗中起着关键作用,因为许多抗癌治疗药物的生物靶标是细胞核。然而,多种生理屏障限制了游离药物的递送效率,导致治疗效果不理想。在此,我们探索了基于硫代缩醛交联聚磷酸酯的纳米粒作为一种具有肿瘤酸性(pH)敏感转录激活因子(TAT)肽(DA 掩蔽 TAT 修饰的活性氧(ROS)敏感 Ce6/DOX 负载超支化纳米粒(TRCD)),用于级联细胞核靶向药物递送。给药后,TRCD 通过掩蔽其 TAT 肽的靶向作用而延长循环时间,然后通过在肿瘤组织中重新激活 TAT 靶向能力来实现增强的肿瘤细胞摄取和改善向核周区域的转位。随后,TRCD 在 660nm 激光下产生的 ROS 不仅破坏核膜以允许进入细胞核,而且还触发细胞核内有效载荷的细胞内释放。体内实验证明,这种 pH/光双重敏感的聚合物纳米载体具有显著的治疗效果,能够有效抑制肿瘤生长。这种多阶段级联细胞核靶向药物递送概念为开发细胞核靶向药物递送系统提供了新途径。